Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zampilimab dose-finding study in idiopathic pulmonary fibrosis
2024-514246-37-00Phase 2Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of Zampilimab in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Planned start Apr 2026; status: authorised.
02
Drugs
Zampilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-514246-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514246-37-00.